Heron Therapeutics (HRTX) Shares Gap Down to $41.45

Heron Therapeutics Inc (NASDAQ:HRTX) shares gapped down before the market opened on Tuesday . The stock had previously closed at $43.40, but opened at $41.45. Heron Therapeutics shares last traded at $40.55, with a volume of 3842551 shares.

Several research firms have recently weighed in on HRTX. Cantor Fitzgerald set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. Leerink Swann increased their price target on Heron Therapeutics to $46.00 and gave the stock an “outperform” rating in a research note on Friday. BidaskClub downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 17th. Oppenheimer increased their price target on Heron Therapeutics from $34.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of Heron Therapeutics in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $42.38.

The company has a market capitalization of $2.98 billion, a P/E ratio of 11.11 and a beta of 1.87.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.06. Heron Therapeutics had a negative return on equity of 239.94% and a negative net margin of 515.27%. The business had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.10 million. The company’s quarterly revenue was up 222.2% on a year-over-year basis. equities research analysts predict that Heron Therapeutics Inc will post -2.38 earnings per share for the current year.

In other news, CEO Barry D. Quart sold 50,000 shares of Heron Therapeutics stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $39.05, for a total transaction of $1,952,500.00. Following the completion of the sale, the chief executive officer now owns 69,600 shares in the company, valued at approximately $2,717,880. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kevin C. Tang purchased 192,308 shares of the company’s stock in a transaction dated Thursday, March 29th. The shares were acquired at an average price of $26.00 per share, with a total value of $5,000,008.00. The disclosure for this purchase can be found here. 16.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $117,000. SG Americas Securities LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $183,000. Ellington Management Group LLC bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $195,000. Pinnacle Associates Ltd. bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $201,000. Finally, Jefferies Group LLC bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $214,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply